Please provide your email address to receive an email when new articles are posted on . A novel TAVR system was safe and effective for adults with severe aortic regurgitation who are not surgical ...

Please provide your email address to receive an email when new articles are posted on . A novel system for transcatheter aortic valve replacement was safe and effective for a small cohort of patients ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the 2025 Transcatheter Cardiovascular Therapeutics (TCT) ...

SAN FRANCISCO, CA—The Trilogy heart valve system (JenaValve) performs well in patients who have symptomatic aortic regurgitation (AR) and a high surgical risk, according to the results of the ALIGN-AR ...

NEW YORK, NY—For patients with pure native aortic regurgitation (AR) who are undergoing TAVI, use of devices tailored to treat the AR seems to provide superior outcomes compared with off-label use of ...

BURLINGAME, Calif., Oct. 23, 2023 /PRNewswire/ -- Genesis MedTech, a leading medical device company, today announced initiation of enrolment in its North American Early Feasibility Study using its ...

-First study presented by Nick Amoroso, MD, at the TVT Structural Heart Summit in Phoenix, Arizona - ALISO VIEJO, Calif.--(BUSINESS WIRE)--egnite, Inc., a leading digital health company for ...

Among young adults with aortic regurgitation (AR), those undergoing aortic valve replacement (AVR) before they met standard criteria were more likely to achieve good results from the surgery, a study ...

People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...